Editas shares have added about 25.4% since the beginning of the year versus the S&P 500's gain of 7.8%. What's Next for Editas? Editas Medicine (EDIT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.28 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of +28.57%. A quarter ago, it was expected that this genome editing company would post a loss ...